Last 25.75 TWD
Change Today +0.10 / 0.39%
Volume 890.0K
As of 2:32 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

we&win diversification co lt (4113) Snapshot

Open
25.70
Previous Close
25.65
Day High
25.95
Day Low
25.65
52 Week High
06/5/13 - 27.06
52 Week Low
01/7/14 - 21.40
Market Cap
3.3B
Average Volume 10 Days
699.9K
EPS TTM
5.13
Shares Outstanding
127.4M
EX-Date
08/21/13
P/E TM
5.0x
Dividend
1.07
Dividend Yield
4.15%
Current Stock Chart for WE&WIN DIVERSIFICATION CO LT (4113)

Related News

No related news articles were found.

we&win diversification co lt (4113) Related Businessweek News

No Related Businessweek News Found

we&win diversification co lt (4113) Details

We&Win Diversification Co.,Ltd., a biotechnology company, engages in the development, manufacture, and marketing of monoclonal antibodies for biomedical research and diagnostics in Taiwan and internationally. Its product line includes drug abuse rapid tests (DART), hormone rapid tests (HRT), infectious disease rapid tests (IDRT), and blood transmission disease rapid tests (BTD). The DART product line primarily comprises methamphetamine rapid diagnostic test, a test for determination of methamphetamine and its metabolites in human urine specimens; cocaine rapid diagnostic test, used for determination of cocaine's metabolite and benzoylecgonine in human urine specimens; and amphetamine rapid diagnostic test, used for determination of amphetamine and its metabolites in human urine specimens. The HRT product line includes hCG rapid test, a chromatographic immunoassay for the detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy; and LH ovulation test, which detects luteinizing hormone surge in urine. The IDRT product line comprises helicobacter pylori antibody rapid test, used for the detection of antibodies against helicobacter pylori; syphilis antibody rapid test, used for determination of antibodies to treponema pallidum in human serum specimens as an aid in the diagnostic of syphilis; and mycobacterium tuberculosis antibody rapid test, used for detection of antibodies isotypes against TP. The BTD product line includes HCV antibody rapid test, used for the detection of antibody to hepatitis C virus in serum or plasma; HBV surface antigen rapid test, used for detection of HBV infection from patient's serum or plasma specimens; and HIV-1/2 antibody rapid test, an initial screening test for the detection of HIV-1/2 from patient's serum or plasma specimens. The company markets its products primarily through distributors, as well as through online. We&Win Diversification Co.,Ltd. is headquartered in Kaoshung, Taiwan.

we&win diversification co lt (4113) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

we&win diversification co lt (4113) Key Developments

We&Win Diversification Co.,Ltd., Annual General Meeting, Jun 26, 2013

We&Win Diversification Co.,Ltd., Annual General Meeting, Jun 26, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4113:TT 25.75 TWD +0.10

4113 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4113.
View Industry Companies
 

Industry Analysis

4113

Industry Average

Valuation 4113 Industry Range
Price/Earnings 5.8x
Price/Sales 1.5x
Price/Book 1.2x
Price/Cash Flow 5.7x
TEV/Sales 0.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WE&WIN DIVERSIFICATION CO LT, please visit kh.vvvvv.com.tw. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.